glp-1 and eye disease The protective role of in neuro-ophthalmology GLP-1 Drugs and Vision Loss:

For individuals with underlying health conditions such as type 2 diabetes mellitus or obesity, inadequate dosing could increase the risk of long-term complications such as uncontrolled diabetes, kidney diseases, and cardiovascular diseases associated with type 2 diabetes and obesity

Retatrutide is not affected by food in the same way oral medications are it's a subcutaneous injection, absorbed through the lymphatic system independent of digestion

The semaglutide versus tirzepatide comparison helps weigh the options

Insulin secretagogues: sulfonylureas They stimulate insulin secretion and are associated with a higher risk of severe hypoglycemia than metformin and other drugs in patients with advanced age and chronic liver or kidney disease.56 They do not modify IR and their effect may be limited in alcoholic individuals due to damage of the beta cells of pancreatic islets.57 Tolbutamide is not recommended in patients with liver disease since half-life increases over 50%.58 Glibenclamide (glyburide) and gliclazide are metabolized in the liver and eliminated through bile and kidney